Products Categories
CAS No.: | 32838-28-1 |
---|---|
Name: | Butoctamide |
Molecular Structure: | |
Formula: | C16H29 N O5 |
Molecular Weight: | 315.46 |
Synonyms: | Butanedioicacid, mono[3-[(2-ethylhexyl)amino]-1-methyl-3-oxopropyl] ester (9CI); Succinicacid, monoester with N-(2-ethylhexyl)-3-hydroxybutyramide (8CI); BAHS;Butoctamide hydrogen succinate; Butoctamide succinate; Listomin S; M 2H; M 2H(ester); N-(2-Ethylhexyl)-3-hydroxybutyramide semisuccinate; N-(2-Ethylhexyl)-b-hydroxybutyramide semisuccinate;N-2-Ethylhexyl-b-oxybutyramidesemisuccinate |
Density: | 1.06g/cm3 |
Melting Point: | 46.5° |
Boiling Point: | 514.6°Cat760mmHg |
Flash Point: | 265°C |
Safety: | Moderately toxic by intraperitoneal, ingestion and subcutaneous routes. An experimental teratogen. When heated to decomposition it emits toxic fumes of NOx. |
PSA: | 96.19000 |
LogP: | 3.34590 |
Butoctamide semisuccinate ,its CAS register number 32838-28-1,it's also named as BAHS ; Butanedioic acid, mono[3-[(2-ethylhexyl)amino]-1-methyl-3-oxopropyl] ester ; Butoctamide hydrogen succinate ; Butoctamide semisuccinate ; Listomin S ; Butoctamide hemisuccinate ; M-2H ; CID2486 ,and so on.
IUPAC Name: 4-[4-(2-Ethylhexylamino)-4-oxobutan-2-yl]oxy-4-oxobutanoic acid
CAS: 32838-28-1
Molecular Formula: C16H29NO5
Molecular Weight: 315.4052
Molecular structure:
ACD/LogD (pH 5.5): 1.56
ACD/LogD (pH 7.4): -0.24
ACD/BCF (pH 5.5): 4.75
ACD/BCF (pH 7.4): 1
ACD/KOC (pH 5.5): 49.76
ACD/KOC (pH 7.4): 1
H bond acceptors: 6
H bond donors: 2
Freely Rotating Bonds: 13
Index of Refraction: 1.47
Molar Refractivity: 83.05 cm3
Molar Volume: 297.4 cm3
Polarizability: 32.92 10-24cm3
Surface Tension: 38.9 dyne/cm
Density: 1.06 g/cm3
Flash Point: 265 °C
Enthalpy of Vaporization: 86.05 kJ/mol
Boiling Point: 514.6 °C at 760 mmHg
Vapour Pressure: 5.61E-12 mmHg at 25°C
Butoctamide semisuccinate (CAS No.32838-28-1) is supposed to be used as pharmaceutical intermediate.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intraperitoneal | 473mg/kg (473mg/kg) | Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 18, Pg. 648, 1971. | |
mouse | LD50 | oral | 5600mg/kg (5600mg/kg) | BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 18, Pg. 648, 1971. |
mouse | LD50 | subcutaneous | 3130mg/kg (3130mg/kg) | Drugs in Japan Vol. -, Pg. 1098, 1995. | |
rat | LD50 | intraperitoneal | 635mg/kg (635mg/kg) | Toho Igakkai Zasshi. Journal of Medical Society of Toho University. Vol. 18, Pg. 648, 1971. | |
rat | LD50 | oral | 12100mg/kg (12100mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 24, Pg. 2029, 1982. | |
rat | LD50 | subcutaneous | 2510mg/kg (2510mg/kg) | Drugs in Japan Vol. -, Pg. 1098, 1995. |
Moderately toxic by intraperitoneal, ingestion and subcutaneous routes. An experimental teratogen. When heated to decomposition it emits toxic fumes of NOx.
Removal in wastewater treatment of Butoctamide semisuccinate (CAS No.32838-28-1) can be stated as follows:
Total removal:4.66 percent
Total biodegradation:0.12 percent
Total sludge adsorption:4.55 percent
Total to Air:0.00 percent
(using 10000 hr Bio P,A,S)